for people ages 40 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion



The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Official Title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis


Idiopathic Pulmonary Fibrosis, BMS-986278, LPA1 antagonist, IPF, Pulmonary fibrosis, Fibrosis


You can join if…

Open to people ages 40 years and up

  • Subjects with IPF aged ≥ 40 years at the time of signing the informed consent
  • Diagnosis of IPF within 7 years prior to screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained at screening and verification of usual interstitial pneumonia.
  • If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening
  • If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening.
  • Women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test
  • Men who are sexually active with women of childbearing potential agree to use male barrier contraception

You CAN'T join if...

  • History of stroke or transient ischemic attack within 3 months prior to screening
  • Significant cardiac disease within 6 months prior to screening per the investigator's discretion
  • Participants who have a current malignancy or a previous malignancy in the past 5 years prior to screening, except for those who have a documented history of cured nonmetastatic squamous cell skin carcinoma, basal cell skin carcinoma, or cervical carcinoma in situ.

    Note: Other protocol-defined inclusion/exclusion criteria apply


  • UCSF Medical Center- Pulmonary Practice
    San Francisco California 94143-2202 United States
  • Stanford Hospital And Clinics
    Stanford California 94305 United States


not yet accepting patients
Start Date
Completion Date
Bristol-Myers Squibb
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting Investigator Inquiry Form FDA Safety Alerts and Recalls
Phase 3 research study
Study Type
Expecting 1185 study participants
Last Updated